Abstract:Background: Accurate interpretation of BRCA1/2 variants is critical for risk assessment, enhanced cancer surveillance, prevention strategies, and precise clinical treatment of breast cancer. However, current worldwide standards depend primarily on sequencing information from Caucasian populations.Methods: Panel-based sequencing served to detect BRCA1/2 variants in a Chinese multicenter cohort of 21,216 breast cancer patients (BCs) and 6,434 healthy controls (HCs).Findings: 1,245 pathogenic variants of BRCA1/2, 262 of which were novel (21.04%), and 2,517 variants of uncertain significance (VUS) were identified. Unlike in the Caucasian population, BRCA2 variants were more frequent than BRCA1 variants (56.34% versus 43.66%). The 48 most common variants accounted for 39.86% of all pathogenic variants, and were not reported as common variants in Caucasians. Furthermore, we unambiguously reclassified VUS in 508 subjects, lowering the VUS ratio from 9.05% to 7.21%. Pathogenic BRCA1/2 variants correlated with younger onset age, higher frequencies of bilateral and triple-negative BC, invasive carcinomas, high histological grades, and family history of BC and other cancers.Interpretation: Strong ethnicity-specific occurrences of pathogenic BRCA1/2 variants were identified in the Chinese population. Hence, the findings provide rationale and sequencing information for the implementation of BRCA1/2 variants tailored to the Chinese population into clinical risk assessment.Funding Statement: National Natural Science Foundation of China 81772802, Shanghai science and technology innovation action plan of China 17JC1404400 and 16DZ19102, Special Funds for Technological Innovation of Shanghai Jiao Tong University YG2016MS22, Chinese Academy of Science XDA12020223 (W.H.X), Natural Science Foundation of Zhejiang Province LZ16H160002 (C.Y.D), Zhejiang Provincial Program for the Cultivation of High-level Innovative Health Talents (C.Y.D).Declaration of Interests: Authors declare no potential conflicts of interest.Ethics Approval Statement: The study was approved by the Ethics Committee of all the hospitals involved and was performed according to the Declaration of Helsinki Principles. Written consent to notify blood samples for future research was obtained for each patient under the Institutional Review Board (IRB)-approved protocol.

Prevalence of <i>BRCA1</i>/<i>BRCA2</i> pathogenic variation in Chinese Han population

Prevalence and Reclassification of BRCA1 and BRCA2 Variants in a Large, Unselected Chinese Han Breast Cancer Cohort

Assessing the Variations in Breast/Ovarian Cancer Risk for Chinese BRCA1/2 Carriers

Identification of <i>BRCA1</i>:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

[Analysis of the Mutations of BRCA1 in 9 Familiar Breast Cancer Patients].

Breast cancer risk in BRCA1 and BRCA2 mutation carriers in Chinese Han population

The Prevalence of BRCA1 and BRCA2 Germline Mutations in High-Risk Breast Cancer Patients of Chinese Han Nationality: Two Recurrent Mutations Were Identified

Prevalence and Spectrum of BRCA Germline Variants in Mainland Chinese Familial Breast and Ovarian Cancer Patients.

Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer

<i>BRCA1</i> c.5470_5477del, a founder mutation in Chinese Han breast cancer patients

Prevalence Of Brca1 And Brca2 Gene Mutations In Chinese Patients With High-Risk Breast Cancer

Prevalence and Characterization of BRCA1 and BRCA2 Germline Mutations in Chinese Women with Familial Breast Cancer

Multicenter Cross-Sectional Screening of the BRCA Gene for Chinese High Hereditary Risk Breast Cancer Populations

Retrospective reinterpretation and reclassification of BRCA1/2 variants from Chinese population

Prevalence of BRCA1 and BRCA2 Pathogenic Variants in 8627 Unselected Patients with Breast Cancer: Stratification of Age at Diagnosis, Family History and Molecular Subtype

Breast Cancer Risk Associated with BRCA1 and BRCA2 Pathogenic Variants in the Eastern Chinese Population

BRCA1 and BRCA2 Deleterious Mutation in 219 Han Chinese Hereditary Breast Cancer Patients

Analysis of BRCA1/2 Mutation Spectrum and Prevalence in Unselected Chinese Breast Cancer Patients by Next-Generation Sequencing

The Prevalence of BRCA1 and BRCA2 Mutations in Eastern Chinese Women with Breast Cancer

Breast Cancer Risk in Chinese Women with Brca1 or Brca2 Mutations

Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area